Reproductive Health Global Program

Subcutaneous DMPA (Sayana Press):
Expanding contraceptive access and options

Subscribe to Sayana Press Update

Advocacy Pack for Subcutanous DMPA

Advocacy Pack for Subcutaneous DMPA
Tools for advocacy and communications to increase access to a new type of injectable contraception.

About the product

Sayana® Press is a three-month, progestin-only, all-in-one injectable contraceptive that combines the drug and needle in the Uniject™ injection system. Sayana Press is small, light, easy to use, and requires minimal training, making it especially suitable for community-based distribution—and for women to administer themselves through self-injection. Sayana Press can improve access to a safe and effective contraceptive option, and increase women’s autonomy.

Self-injection with Sayana Press

Self-injection of Sayana Press was officially approved by the United Kingdom’s lead stringent regulatory authority in 2015, and has been recommended by WHO in contexts where women have information, training, and support. Through 2017, PATH is conducting research on self-injection of Sayana Press in collaboration with ministries of health in Senegal and Uganda, and learning how to support women in these settings to self-inject safely and effectively.

Product introduction: Making injections available from new providers

Sayana Press has been available from providers in Senegal, Uganda, Burkina Faso, and Niger since 2014 under a country-led introduction initiative coordinated by PATH. These introductions have helped to make injectable contraception available in remote locations, closer to where women live. Between July 2014 and June 2016, nearly 500,000 doses of Sayana Press were administered by family planning providers in the four countries. To understand the potential impact of Sayana Press administered by providers, PATH and partners are also conducting studies on the effectiveness and cost-effectiveness of Sayana Press administered by clinic-based (Burkina Faso) and community-based (Uganda) health providers; results are anticipated in 2017.

Pricing and regulatory approval of Sayana Press

Under a novel pricing agreement negotiated by Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) in 2014, qualified purchasers in the world’s poorest 69 countries can obtain Sayana Press for US$1 per dose. For more information on this topic, please contact

Sayana Press has regulatory approval in the European Union and more than 25 countries around the world. The formulation of depot medroxyprogesterone acetate (DMPA) used in Sayana Press is also approved in the United States.

Learn more about Sayana Press

PATH Sayana Press key fact sheets



Sayana Press Update newsletters

Subscribe to Sayana Press Update



PATH blog posts and features about Sayana Press

PATH announcements about Sayana Press

Sayana Press and Depo-Provera are registered trademarks of Pfizer Inc. Uniject is a trademark of BD.

Sayana Press was approved in the European Union via procedure number UK/H/0960/002UK/H/0960/002. The UK was the Reference Member State. A Public Assessment Report is available at the Heads of Medicines Agency website and the Medicines and Healthcare Products Regulatory Agency web page.